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Abstract
Background: Currently there are no effective treatments for many neurodegenerative diseases. Reliable biomarkers
for identifying and stratifying these diseases will be important in the development of future novel therapies. Lewy
Body Dementia (LBD) is considered an under diagnosed form of dementia for which markers are needed to
discriminate LBD from other forms of dementia such as Alzheimer’s Disease (AD). This work describes a Label-Free
proteomic profiling analysis of cerebral spinal fluid (CSF) from non-neurodegenerative controls and patients with
LBD. Using this technology we identified several potential novel markers for LBD. These were then combined with
other biomarkers from previously published studies, to create a 10 min multiplexed targeted and translational
MRM-LC-MS/MS assay. This test was used to validate our new assay in a larger cohort of samples including controls
and the other neurodegenerative conditions of Alzheimer’s and Parkinson’s disease (PD).
Results: Thirty eight proteins showed significantly (p < 0.05) altered expression in LBD CSF by proteomic
profiling. The targeted MRM-LC-MS/MS assay revealed 4 proteins that were specific for the identification of
AD from LBD: ectonucleotide pyrophosphatase/phosphodiesterase 2 (p < 0.0001), lysosome-associated
membrane protein 1 (p < 0.0001), pro-orexin (p < 0.0017) and transthyretin (p < 0.0001). Nineteen proteins were
elevated significantly in both AD and LBD versus the control group of which 4 proteins are novel (malate
dehydrogenase 1, serum amyloid A4, GM2−activator protein, and prosaposin). Protein-DJ1 was only elevated
significantly in the PD group and not in either LBD or AD samples. Correlations with Alzheimer-associated
amyloid β-42 levels, determined by ELISA, were observed for transthyretin, GM2 activator protein and IGF2 in
the AD disease group (r2 ≥ 0.39, p ≤ 0.012). Cystatin C, ubiquitin and osteopontin showed a strong significant
linear relationship (r2 ≥ 0.4, p ≤ 0.03) with phosphorylated–tau levels in all groups, whilst malate
dehydrogenase and apolipoprotein E demonstrated a linear relationship with phosphorylated-tau and total-tau
levels in only AD and LBD disease groups.
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Conclusions: Using proteomics we have identified several potential and novel markers of neurodegeneration
and subsequently validated them using a rapid, multiplexed mass spectral test. This targeted proteomic
platform can measure common markers of neurodegeneration that correlate with existing diagnostic makers
as well as some that have potential to show changes between AD from LBD.
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Background
The global impact of dementia is increasing rapidly with
150 million people estimated to be affected worldwide
by 2015. This is largely due to neurodegenerative disor-
ders such as Alzheimer’s disease (AD) and Lewy body
dementia (LBD) [1]. Neurodegenerative diseases, like
Parkinson’s disease (PD), are also common and cause
significant morbidity. These disorders are all strongly
age-related and the expected increase in patients with
these long-term conditions presents a huge social and
economic challenge. Therefore, there is an urgent need
to find treatments that will slow, delay or prevent these
diseases. Accurate diagnosis of neurodegenerative dis-
ease will be crucial to treatment development and ultim-
ately, to our ability to offer earlier effective therapeutic
interventions. Definitive diagnosis in non-genetic neuro-
degenerative disorders can currently only be made with
histopathological confirmation, and usually only at post-
mortem examination [2]. In vivo clinical diagnosis of
neurodegenerative disorders (AD, LBD etc.) is difficult
especially in the earliest stages: specialist centres typic-
ally only achieve an accurate pre-mortem diagnosis in
70–90 % of cases [2]. Therefore, there is a pressing need
for efficient, cost-effective biomarkers that can help
diagnose patients earlier and more accurately. Further-
more there is increasing recognition that the majority of
neurodegenerative diseases have long pre-clinical stages.
In addition, for treatments to be effective it may be ne-
cessary to initiate treatments well before the onset of
symptoms and for this to occur a diagnosis will almost
certainly rely on biomarkers. The availability of bio-
markers for different neurodegenerative conditions with
overlapping symptoms but different aetiologies therefore
represents a critical issue for the future availability of
disease-modifying treatments. The potential utility of
cerebrospinal fluid (CSF) biomarkers in neurodegenera-
tion has been shown by the development of β amyloid
1–42 (Aβ42), total tau protein (h-tau), and phosphory-
lated tau 181 (p-tau) assays; these are now well estab-
lished as diagnostic biomarkers of AD and have entered
routine clinical practice [3]. Lewy body dementia in par-
ticular has a much lower incidence than AD with an es-
timate of 3.5 cases per 100,000 per year [4] and is widely
accepted to be highly under diagnosed and is the most
frequently misdiagnosed form of dementia. Markers for
LBD are greatly needed therefore the profiling part of
this study was focused on identifying an LBD CSF pro-
tein signature that could then be tested against other
neurodegenerative conditions such as AD and PD. Fig. 1
illustrates the experimental design of the 3 stages of this
study. Thus, this work set out to i) perform an in-depth
biomarker discovery experiment to identify potentially
unique CSF protein signatures for neurodegenerative
conditions with the focus on LBD ii) combine these new
biomarkers, with conventional biomarkers and potential
biomarkers described previously in the literature [5–14],
into a rapid, high-throughput and multiplexed test iii)
validate these new markers alongside previously de-
scribed biomarkers in a larger multicentre cohort of
samples from patients with AD, PD and LBD.
In summary, this work describes a biomarker discovery
type experiment using LBD patient CSF which allowed
us to identify several proteins not described previously.
In addition, we have developed this further into a ‘one-
pot’ targeted proteomic translational assay, capable of
quantitating 46 potential biomarkers in under 10 min
and using only 100 μl of CSF. Using this targeted prote-
omics method we were able to validate 4 novel markers
for LBD and AD from 2 separate dementia centre
cohorts.
Results
Biomarker discovery (Label Free Quantitative Proteomics)
In total, >1000 proteins were detected in 400 μl of de-
pleted CSF by label free quantitative proteomic analyses.
Analysis of the LBD CSF proteome demonstrated 40
proteins were significantly altered with 22 proteins by a
factor of 2-fold or more when compared to the control
group (Additional file 1: Table S1). Gene Ontology ana-
lysis of the’cellular component’ in the LBD CSF revealed
the majority were secretory in origin (71 %) but also a
significant proportion were cytosolic (21 %) and interest-
ingly 7 % were determined to be involved in cell junc-
tions (Additional file 2: Figure S1). Using Webgestaldt
gene analysis tools [15] those genes found to be dysregu-
lated in the LBD group were observed to be involved in
‘wound healing’ ‘defence response’, the ‘inflammatory
response’ and ‘regulation of the response to external
stimulus’. In addition, ‘negative regulation of blood
coagulation / homestasis’ was observed in 12 genes, 6
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genes involved in proteoglycan homeostasis, 5 genes in-
volved in platelet degranulation and 6 genes involved in
proteolysis. In the molecular function category, 12 genes in-
volved in carbohydrate binding, 3 in phospholipid binding
and 44 genes involved in biopeptide production, enzyme
activity/regulation, peptidase regulation and inhibition.
Targeted proteomic MRM LC-MS/MS assay
Table 1 summarises all the proteins that were found sig-
nificantly altered compared to controls in this study.
Based on fold-change (>1.5) and quality of the MS data,
potential biomarkers identified in the discovery experi-
ments were selected for validation by their development
into a multiplexed 10 min, targeted proteomic triple
quadrupole, peptide MRM-based assay. Chitinase-3-like
protein 1 (YKL-40) and Apolipoprotein E were signifi-
cant in the label free proteomics analyses but at a cut off
of less than 1.5 fold. However as they have been de-
scribed previously as neurodegeneration markers they
were included in the assay to assess them with the other
potential markers. Selected AD or PD specific markers
described previously in the literature were also included
[5–14] in order to compare with LBD. Using timed, or
dynamic MRMs, in an UPLC-MS/MS assay, we created
a method capable of analysing 74 peptides from 54
proteins using 100 μl of CSF. The full list of biomarkers
put forward for validation is given in Additional file 3:
Table S2. Out of these 54 potential biomarkers, only 27
resulted in being statistically significant and/or have po-
tential for diagnostic use (Table 1). Fig. 2 includes an
overlaid chromatogram of the UPLC-MS/MS chromato-
gram of the final successful targeted proteomic assay
depicting the majority of the proteins/peptide biomarkers.
Alzheimer’s disease specific biomarkers
The MRM-based mass spectral analysis demonstrated
that 4 biomarkers (pro-orexin, LAMP1, transthyretin
and ectonucleotide pyrophosphatase/phosphodiesterase
2 (ENPP2/autotaxin)) were statistically significantly ele-
vated in the CSF of AD versus the control cohort
(Table 1, Fig. 3) and not in the LBD samples. Two of the
four biomarkers have not been described previously as
potential diagnostic proteins for Alzheimer’s disease
(LAMP1 and ENPP2). ENPP2 was the most statistically
significant of all the biomarkers (p < 0.0001) and exhib-
ited an approximate 1.7-fold elevation compared to the
control cohort. The biomarkers with the greatest fold in-
crease in the AD (Table 1) were osteopontin, carnosine
dipeptidase 1 (CNDP1) and malate dehydrogenase, and
were approximately 4.7-, 3.4-, 3.2- and 3.2-fold higher in
the AD group compared to the control cohort, respect-
ively. However, although these proteins demonstrated
the highest-fold mean increase in the AD versus control
group, none were disease specific for AD.
Alzheimer’s disease and Lewy body dementia related
biomarkers
A total of 23 protein biomarkers were observed to be
statistically significantly elevated in the AD and LBD
groups compared to the control group (Table 1, Figs. 4,
Fig. 1 Graphical summary of the work carried out ‘from biomarker discovery to validation’. Proteins found in the proteomic profiling experiment
were incorporated into a targeted MRM-LC-MS/MS based assay along with other markers in the literature
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Table 1 Summary of results of potential makers validated using a targeted proteomic mass spectrometry test
Alzheimer’s disease Lewy body dementia Parkinson’s disease
Protein biomarker Fold-change (statistical significance) Protein biomarker Fold-change (statistical significance) Protein biomarker Fold-change (statistical significance)
Osteopontin 4.7 (p < 0.002) DJ1 3.1 (p < 0.0053)
Osteopontin 2.3 (p < 0.02) aMalate dehydrogenase 2.2 (not significant)
CNDP1 3.2 (p < 0.0001) aUCHL1 2.2 (p < 0.01) aLSAMP 1.9 (p < 0.0136)
aMalate dehydrogenase 3.2 (p < 0.0001) Chitinase-3-like protein 1 2.1 (p < 0.0004) Apolipoprotein H 1.8 (p < 0.0484)
Apolipoprotein E 2.9 (p < 0.0001) aGM2 Activator Protein 1.9 (p < 0.0087) Serum Amyloid A4 1.7 (not significant)
Ubiquitin 2.3 (p < 0.0015) aMalate dehydrogenase 1.9 (p < 0.0082) Pro-orexin 1.6 (not significant)
aGM2 Activator Protein 2.3 (p < 0.0002)
aSerum Amyloid A4 1.9 (p < 0.0092) Osteopontin 1.6 (p < 0.02)
IBP2 2.3 (p < 0.0001) Apolipoprotein E 1.7 (p < 0.0014) UCHL1 1.5 (not significant)
aSerum Amyloid A4 2.3 (p < 0.0007) CNDP1 1.7 (p < 0.0039) Prosaposin 1.5 (not significant)
aPro-orexin 2.2 (p < 0.0017) Apolipoprotein H 1.7 (p < 0.01) Vitamin D binding protein 1.5 (p = 0.05)
aCarboxypeptidase E 2.2 (p < 0.0001) aProsaposin 1.7 (p < 0.02) Chitinase-3-like protein 1 1.4 (not significant)
Apolipoprotein H 2.2 (p < 0.0001) S100B 1.7 (p < 0.031) GM2 Activator Protein 1.3 (not significant)
Chitinase-3-like protein 1 2.2 (p < 0.0012) Ubiquitin 1.6 (p < 0.011) S100B 1.3 (not significant)
aprosaposin 2.1 (p < 0.0001) Insulin-like growth factor 2 1.6 (p < 0.0052) Apolipoprotein E 1.2 (not significant)
aUCHL1 2 (p < 0.0108) Cystatin C 1.6 (p < 0.002) CNDP1 1.2 (not significant)
aLAMP1 2 (p < 0.0003) Vitamin D binding protein 1.6 (p < 0.01) Clusterin 1.2 (not significant)
Cystatin C 1.9 (p < 0.0001) IBP2 1.6 (p < 0.0052) Cystatin C 1.2 (not significant)
Vitamin D binding protein 1.9 (p < 0.0001) LAMP1 1.5 (not significant) Transferrin 1.2 (not significant)
Transthyretin 1.8 (p < 0.0001) aCarboxypeptidase E 1.5 (p < 0.0097) LAMP1 1.1 (not significant)
Insulin-like growth factor 2 1.8 (p < 0.0015) aTREM 2 1.5 (p < 0.0062) Carboxypeptidase E 1.1 (not significant)
aTREM 2 1.8 (p < 0.0003) aLSAMP 1.5 (p < 0.0004) TIMP1 1.1 (not significant)
aLSAMP 1.8 (0.0009) Pro-orexin 1.4 (not significant) Insulin-like growth factor 2 1.1 (not significant)
ENPP2 a1.7 (p < 0.0001) Clusterin 1.4 (p < 0.0102) TREM 2 1.1 (not significant)
S100B 1.7 (p < 0.0037) TIMP1 1.4 (p < 0.0055) IBP2 1.1 (not significant)
Clusterin 1.6 (p < 0.0001) Transferrin 1.4 (p < 0.01) Transthyretin 1 (not significant)
Transferrin 1.4 (p < 0.0015) Transthyretin 1.1 (not significant) Ubiquitin 0.9 (not significant)
TIMP1 1.3 (p < 0.018) ENPP2 1 (not significant) ENPP2 0.8 (not significant)
The fold-change in the expression of each protein biomarker relative to the control group, are shown in the second column with their p value determined by Mann-Witney U test shown in parenthis below it
aDenotes new markers not described previously as being potential neurodegenerative markers
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5 and 6). Of these 23 proteins, 6 proteins had not been
described previously as being potential markers of neu-
rodegeneration in LBD and AD. As described earlier,
ENPP2 (autotaxin) and LAMP1, were able to distinguish
AD from LBD. Figure 4 shows proteins elevated in both
AD and LBD compared to control. These proteins also
are even significantly higher in AD compared LBD. Pro-
teins that are also elevated but not statistically signifi-
cantly between LBD and AD are shown in Fig. 5. These
consist of mainly the validated markers in this study and
are likely markers of non-specific neurodegeneration. In
similarity to the AD specific results, those biomarkers
Fig. 2 Overlaid chromatogram of the marker peptides included in the multiplexed targeted proteomic assay. The assay was developed to
quantitate 74 peptides in a 10 min LC run. Markers significant in the study are shown in the above overlaid chromatogram except for transferrin,
serum amyloid A4 and apolipoprotein E which are not shown due to interference from other peaks. All markers are shown individually as
endogenous and spiked in Additional file 8: Figure S2
Fig. 3 Alzheimer’s disease Specific Markers Graphs showing the results of the multiplexed MRM-based LC-MS/MS assay of protein biomarkers
quantitated in the CSF of control. Lewy body dementia (LBD). Parkinson’s disease (PD) and Alzheimer’s disease (AD). All 4 markers show changes
in AD specific from other neurodegenerative disease groups and controls. No significant changes are observed in the PD group *
Denotes new marker not described previously
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most statistically significantly elevated in the LBD group
versus controls, did not demonstrate the greatest fold
change in elevation. Those biomarkers showing the great-
est fold-change in elevation were osteopontin (2.3-fold),
UCHL1 (2.2-fold) and chitinase-3-like protein 1 (2.1-fold,
Table 1). Of those biomarkers demonstrating the greatest
fold-change in elevation in the LBD group, 5 out of the
top 7, had never been described previously as being poten-
tial biomarkers for the diagnosis of LBD (UCHL1, GM2
activator protein, malate dehydrogenase, serum amyloid
A4, Table 1).
Parkinson’s disease and non-specific neurodegeneration
biomarkers
Only one protein, DJ1, was significantly elevated in the
Parkinson’s disease group compared to the control co-
hort (Fig. 6d). DJ1 was the most statistically significant
for PD but also the biomarker demonstrating the great-
est fold-change in elevation (3.1-fold higher than the
mean control concentration, Table 1). However, whilst
DJ1 was elevated compared to controls in PD, it was not
statistically elevated compared to the LBD and AD
groups. In total, only 4 biomarkers were statistically
elevated in the PD group versus controls and included
DJ1 (p < 0.0053), LSAMP (p < 0.0136), apolipoprotein H
(p < 0.0484) and osteopontin (p < 0.02,) (Fig. 6).
Three biomarkers were significantly elevated in all
disease groups compared to the controls (Fig. 6). These
biomarkers were apolipoprotein H, osteopontin and
LSAMP. Apolipoprotein H was 1.7-fold (p < 0.0014), 1.8-
fold (p < 0.048) and 2.2-fold (p < 0.0001) elevated in the
LBD, PD and AD groups, respectively, relative to the
control cohort. Similarly, osteopontin was observed to
be 2.3-fold (p < 0.02), 1.6-fold (p < 0.02) and 4.7-fold
(p < 0.002) elevated in the LBD, PD and AD groups,
respectively. Finally, LSAMP also demonstrated sig-
nificant fold-changes and elevation in all of the neu-
rodegenerative groups of LBD, PD and AD’s relative
to the control group of 1.5-fold (p < 0.0004), 1.9-fold
(p < 0.0136) and 1.8-fold (p < 0.0009) increases versus
the mean of the control group (Table 1, Fig. 6).
Correlation of existing biomarkers Aβ42 and total and
phosphorylated-181 tau with multiplexed test biomarkers
Correlation analyses were performed to compare the
relationship between the current biomarkers analysed
using the conventionally used ELISA-based methods
(total tau (h-tau), p-tau and Aβ42) and the biomarkers
developed into the targeted proteomics assay developed
in this study. PD samples were not investigated due to
the smaller sample number for this group. Correlation
analysis was performed on all markers for the control,
Fig. 4 Common dementia markers that are significantly elevated in AD compared to LBD. Graphs a-f show the results of the targeted proteomic
multiplexed assay of protein biomarkers quantitated in the CSF of control, Lewy body dementia, Parkinson’s and Alzheimer’s disease. Graphs a-f
demonstrate the ability of the test to show changes between Lewy Body dementia and Alzheimer’s disease. No significant changes are observed
in the PD group.* Denotes new biomarkers not described previously
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LBD and AD groups individually with h-tau, p-tau and
Aβ42 and results are summarised in Additional file 4:
Table S3 and individual graphs are given in Additional
file 5: Figure S3, Additional file 6: Figure S4 and Add-
itional file 7: Figure S5.
Transthyretin a marker known to correlate with Aβ42
[16] demonstrated a strong relationship with Aβ42
(Fig. 7a (i)) and p-tau (Fig. 7b (i)) in the AD group but
no correlation was observed in the LBD group. This was
also noted for IGF2 although the correlation with Aβ42
was weaker (Fig. 7a (ii)). Other strongly associated
markers with Aβ42 in AD were GM2 activator protein,
chitinase-3-like protein 1 and cystatin C (Additional file
5: Figure S3 and Additional file 4: Table S3).
Three markers cystatin C, osteopontin and ubiquitin
showed either a strong or weak association of p-tau in
the control group as well as both LBD and AD groups
indicating a specific association of these proteins with p-
tau levels. CNDP1, apoE and malate dehydrogenase
demonstrated strong association of p-tau in both LBD
and AD but not in control (Fig. 7b). ApoE and malate
dehydrogenase also showed a significant correlation with
total tau levels as well as p-tau. Many of the markers did
not show any correlation with Aβ42, p-tau and total tau
therefore their association with AD and LBD is likely in-
dependent from the Aβ42 and tau pathology.
Discussion
There is a growing need for new and more specific bio-
markers in neurodegenerative diseases. The development
of new tests will allow us to diagnose these conditions
more specifically, and preferentially pre-symptomatically,
Fig. 5 Common dementia markers for LBD and AD. Results of the targeted proteomic multiplexed assay of protein biomarkers quantitated in the
CSF. Graphs a-m show significant changes in Lewy body dementia, and Alzheimer’s disease compared to controls. No significant changes are
observed in the PD group * Denotes new biomarkers not described previously
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if we are going to develop new therapies and test their
efficacy. For this to occur, there is a need for a more effi-
cient process of taking any potential biomarkers discov-
ered in hypothesis generating experiments and
developing them into translational tests suitable for
rapid clinical evaluation. We believe this work describes
an effective and streamlined process of improving the
bottle neck of validating and getting new potential bio-
markers to the clinic.
Markers for LBD are in need due to the difficulty in
discriminating LBD from AD clinically. Using Label Free
quantitative proteomics on LBD CSF we were able to
identify several biochemical processes and pathways that
were disrupted or perturbed in LBD CSF. Proteins with
the potential for diagnostic use were developed into a
10 min, multiplexed, targeted MRM-LC-MS/MS test
using a triple quadrupole mass spectrometry based plat-
form (UPLC-MS/MS). The rationale behind the basing
of translational tests onto a UPLC-MS/MS as a platform,
is that this multiplex targeted proteomic methodology
has been proven to be previously beneficial in dementia
research [17, 18]. Targeted MRM based proteomic tests
are gaining interest in the clinical research field [19, 20]
due to its potential to measure multiple markers in one
assay and does not have the cost or problems often
encountered with the use of antibodies [19, 21]. The
assay described in this study had been developed to
streamline this method considerably creating a single a
‘one pot’ test with a 10 min LC gradient, with conse-
quent high throughput capability and potential for clin-
ical translation. We validated the test and markers on a
larger multicentre cohort of samples including AD, LBD
and controls. We were also able to include a cohort of
PD CSF samples to compare with the groups and iden-
tify markers for overall neurodegeneration. Lumbar
puncture is not part of the typical clinical workup for
the diagnosis of PD and is usually carried out on re-
search purposes only, hence samples are harder to ob-
tain but were included to highlight the importance of
these results in comparison with the other neurodegen-
erative diseases. Fig. 8 summaries all the CSF biomarkers
that were specific for each neurodegenerative condition
and those common to each. Only 4 biomarkers detected
were specific for AD (Fig. 3) with ENPP2 (autotaxin)
having not been described previously as a potential CSF
marker of neurodegeneration. Using genetic studies,
ENPP2/autotaxin has been described by Umemura et al.
[22] as being expressed differentially in the frontal cortex
of Alzheimer-type dementia (ATD) patients compared
with those of non-AD controls but not the actual
Fig. 6 Non-specific markers of neurodegeneration and Protein DJ1 as a marker for Parkinson’s disease. Graphs a-d show the results of the
targeted proteomic multiplexed assay of protein biomarkers quantitated in the CSF of control, Lewy body dementia, Parkinson’s and Alzheimer’s
disease. Graphs a-c show biomarkers that show significant changes in all disease groups compared to controls. Protein DJ1 (d) shows only a
significant change in Parkinson’s disease compared to controls. * Denotes new biomarkers not described previously
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Fig. 7 (See legend on next page.)
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protein levels in brain or CSF. ENPP2/autotaxin is a
lysophospholipase that acts on lysophosphatidylcholine
converting it into lysophosphatidic acid (LPA). LPA is a
potent mitogen and has been described previously as hav-
ing a potential contributory role in AD pathology includ-
ing Aβ42 formation [23] increased Tau-phosphorylation
and neurite retraction in neuronal cells [24]. Indeed
Hwang et al. have shown that LPA metabolism maybe a
potential target for AD therapy by the use of gintonin as a
LPA receptor activating ligand. Gintonin, an extract from
ginseng, was shown to attenuate amyloid plaque forma-
tion and memory impairment in a transgenic mouse
model of AD [25]. The other AD specific markers orexin,
and LAMP1 have been either described previously or pos-
tulated as being potential CSF biomarkers of AD and thus
provide confirmation and validation of the methodology
developed in this work [10, 26]. We also included the
recently described AD related microglia and macrophage
membrane-bound receptor TREM2. Several TREM2
mutations have been identified recently that increase the
risk of AD, frontotemporal dementia, PD, and amyo-
trophic lateral sclerosis [27]. Whilst a lot of research has
been performed on the effect of TREM2 variants little has
been done to investigate the normal function of TREM2.
This study shows that CSF levels of TREM2 are increased
in LBD and AD. CSF TREM2 has not been described ele-
vated in dementia. However it has been described in the
brain pathology of AD patients [28] and in the CSF of pa-
tients with multiple sclerosis and CNS inflammation [29].
This indicates that TREM2 may be an overall neuro-
inflammatory marker. ENPP2 (autotaxin) and transthyre-
tin were the most statistically significantly elevated
biomarkers (Table 1) and provided complete discrimin-
ation between the AD and LBD cohorts. The use of these
two biomarkers may provide significant diagnostic value
for help in deciding treatment regimens by allowing better
discrimination of AD from LBD. Transthyretin has been
shown previously to be present in amyloid plaques and
(See figure on previous page.)
Fig. 7 Correlation analysis of multiplexed potential markers with diagnostic ELISA data of the currently used clinical markers. a i-iii show markers
transthyretin, IGF2 and GM2 activator protein in the AD group which correlate significantly with Aβ1-42 levels (measured by ELISA) in the AD
group. There were no correlations observed for any of the markers in the LBD and control groups. b i-ii show markers transthyretin and IGF2
which correlate significantly with p-tau (ELISA data) only in the AD group. iii-v show markers cystatin C, ubiquitin and osteopontin which correlate
with p-tau in all groups indicating that their expression is likely to reflect p-tau expression. vi and vii show markers ApoE and malate dehydrogenase
which correlate with p-tau in both AD and LBD disease groups. viii and ix also show correlation of ApoE and malate dehydrogenase with total tau
(h-tau) expression
Fig. 8 Summarised Venn diagram of the targeted proteomics analysis of the multicentre cohort 2 (AD, LBD, PD and controls). The majority of
markers are dementia specific (common to both LBD and AD). However, although there are no markers specific to LBD, the proteins ENPP2,
transthyretin, pro-orexin and LAMP1 were specific for the AD group. Three markers were elevated in all groups and Protein DJ was specific to
PD. Markers in bold are those discovered in the proteomic profiling experiment. Those with an * are novel markers not previously described
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our data confirms previous findings of a correlation with
Aβ42 levels [16]. However transthyretin is a protein known
to be susceptible to post-translational modifications due its
free thiol group (particularly in CSF) [30]. This makes reli-
able measurement of intact transthyretin using antibodies a
potential problem and may be a reason as to why some
studies have reported reduced levels of transthyretin in AD
CSF [16, 31] whilst our study and another targeted prote-
omic study [17] have reported increased levels. Apolipopro-
tein E has been studied as a potential biomarker previously
in dementia but due to only small changes or ambiguity be-
tween studies, the levels of apolipoprotein E have not been
considered diagnostically useful. The differences in meth-
odologies between mass spec based assays and immunoas-
says may explain why our study finds higher levels of
apolipoprotein E in dementia compared to others [32, 33].
In addition to identifying 4 potential AD specific bio-
markers, a further 19 biomarkers demonstrated a statis-
tically significant elevation in the LBD and AD cohorts
versus the control groups. Of these 19 biomarkers, car-
boxypeptidase E, malate dehydrogenase, serum amyloid
A4, GM2 activator protein, UCHL1 and prosaposin, had
never been described previously as potential CSF bio-
markers for neurodegeneration. The proteins prosaposin
and GM2 activator protein are both chaperone proteins
critical for the lysosomal catabolism of glycosphingoli-
pids. A deficiency in GM2 Activator Protein has also
been associated with the neurological conditions of Tay
Sachs and Sandhoff disease. Although, the reason for
their elevation in the CSF of LBD and AD patients is un-
clear, it is probably as a result of generalised lysosomal
dysfunction as both these proteins have been detected
by the authors in the urine of many different lysosomal
storage diseases [34]. The proteins carboxypeptidase E
and UCHL1 are both processing enzymes involved in
the correct production of neuropeptides/neurohormones
and degradation of ubiquitin monomers in the prote-
asome, respectively. UCHL1 is highly specific to neurons
and its expression has been associated with AD, though
it has also been shown to interact with α-synuclein
another protein implicated in the pathophysiology of
PD. Although our data did not show a significant eleva-
tion of UCHL1 in the CSF of PD patients compared to
the controls.
Little is known about the protein serum amyloid A4
other than it is from the serum amyloid A class of pro-
teins which are a family of apolipoproteins which are
known to be involved in the acute inflammatory re-
sponse. A chronic inflammatory status of neurons is a
known factor associated with neurodegeneration but the
increased levels of serum amyloid A4, a protein synthe-
sised mainly in the liver and adipocytes is unclear.
Finally, malate dehydrogenase was found to be elevated
in LBD, PD and AD groups though only statistically
significantly elevated in the LBD and AD groups. The
role of cytosolic malate dehydrogenase 1 and its eleva-
tion in neurodegeneration is unclear as it is an enzyme
involved in many metabolic pathways and catalyses the
oxidation of malate to oxaloacetate using NAD+. Malate
dehydrogenase is an important protein in the citric acid
cycle and has a prominent role in gluconeogenesis to
create glucose molecules from smaller intermediates. It
is known that most neurodegenerative conditions have a
mitochondrial component, whether primary or second-
ary is unclear. The elevation of malate dehydrogenase in
the CSF may also be a general marker of mitochondrial
dysfunction in its role in the shuttling of malate between
the inner mitochondrial membrane and cystosol. Al-
though malate dehydrogenase was >2-fold elevated in
the PD group it was not statistically significantly ele-
vated. Only the protein DJ1, also known as PARK7, and
a peptidase that is known to have protective role for
neurons against cell death, was found to be both >3-fold
increased and statistically significantly elevated in the
PD group. DJ1 has been shown to be raised in CSF of
PD patients previously but the levels were not significant
compared with LBD and AD samples and the usefulness
of this protein as a diagnostic maker is still to be con-
firmed [11, 35]. This study shows DJ1 can be measured
by targeted proteomics and potentially incorporated into
a multiplex test. α-Synuclein was included in the tar-
geted assay but it was not significantly altered in any of
the groups tested using this method, which is in agree-
ment with earlier studies showing only small or no
changes in the CSF levels of the protein when measured
using immunochemical techniques in synucleinopathies
like LBD and PD [36].
The correlation analysis of the markers with the
established markers given in Additional file 5: Figure
S3, Additional file 6: Figure S4, Additional file 7: Figure
S5 and Fig. 7 gives an insight into the changes occur-
ring from control to disease and indicate the pathology
behind the markers. No correlation with any of the
markers were observed for the LBD group. Only spe-
cific associations could be observed in the AD group
for Aβ42. Transthyretin has been shown previously to
have a linear relationship with Aβ42 CSF levels [16].
Our data did demonstrate a correlation just with AD
and not with LBD and controls (Fig. 7i) confirming this
relationship. Transthyretin also revealed a strong linear
relationship with p-tau and a weak relationship with
total tau levels. IGF2 also showed an AD specific rela-
tionship with Aβ42 and p-tau levels. Many of the
markers revealed correlations with both AD and LBD
(Additional file 4: Table S3) for p-tau and total tau.
Those with the strongest correlations were CNDP1,
apoE, malate dehydrogenase, osteopontin, cystatin C
and ubiquitin. The latter three also showed association
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of p-tau levels in the control group. This indicates these
markers are more directly associated with p-tau and
may only reflect p-tau levels in CSF and therefore have
limited use diagnostically. Many markers did not show
a relationship with either Aβ42, p-tau and total tau
levels and are likely unrelated to the direct pathology of
Aβ42 and tau plaques in AD and LBD. These markers
may indicate other processes ongoing in neurodegener-
ation and warrant further investigation.
One limitation of this study is that some patients with
LBD pathology can also exhibit amyloid plaques [33]. As
with other CSF dementia biomarker studies we acknow-
ledge that we cannot exclude these comorbidities at this
point. Also although there were no statistically signifi-
cant differences between age of patients and controls,
we acknowledge that age ranges between patients and
controls are heterogeneous, and patients are older than
controls. Nevertheless, controls have been followed up
for 1 to 4 years and so far none of them developed de-
mentia. In addition, CSF amyloid, total tau and p-tau
levels in these subjects are within the normal values
(Table 2), suggesting that neither AD-related pathogenic
events nor neurodegenerative ones are occurring.
Conclusions
Multiplexed targeted proteomics is a useful technique
for streamlining biomarker validation. We have validated
markers for neurodegeneration (summary Fig. 8) that
are shared between Alzheimer’s disease, Lewy body
dementia and Parkinson’s disease. Also markers for de-
mentia shared between Alzheimer’s disease and Lewy
body dementia. We have also identified and validated
Alzheimer’s disease specific markers ectonucleotide pyr-
ophosphatase/phosphodiesterase 2, lysosome-associated
membrane protein 1, pro-orexin and transthyretin that
have the potential to discriminate Lewy body dementia
from Alzheimer’s disease. These markers can provide
the clinician with further information towards an
improved diagnosis and also with further future stratifi-
cation pave the way for monitoring of disease progres-
sion for assessment of future potential treatments.
However as with all biomarker discoveries markers will
need to be further validated in a larger cohort of sam-
ples, and with the levels of the biomarkers stratified with
such parameters as disease severity, age of onset and age
after diagnosis.
Methods
CSF sample criteria, collection and routine analysis
Control CSF samples are challenging to obtain and the
samples used in this study have been selected to age
match as closely as possible to the disease cohorts
(Table 2). Multiple correlation analysis of the markers
was performed on the control samples (51–79 years)
and only markers that did not show any significant
change with age are presented in this study.
The experimental design is summarised in Fig. 1. Two
sample cohorts, a biomarker discovery cohort (cohort 1,
n = 28) and a validation cohort (cohort 2, n = 55), were
obtained from two separate centres (University of Milan,
Ospedale Policlinico, Milan, Italy and University of
Gothenburg, Sweden) sharing the same clinical workup.
Sample data is given in Table 2. Regarding patients with
AD, all patients had altered CSF Aβ42, total tau and p-
tau levels, thus confirming the clinical diagnosis [37]
with an accuracy of about 90 %, in accordance with
more recent criteria [38, 39]. LBD diagnosis was made
according to criteria published by McKeith et al. [40].
Table 2 Mean and ± SEM sample data for the two centre cohorts used for the biomarker discovery and validation cohorts
Biomarker discovery cohort Control n = 15 LBD n = 10
Gender (M:F) 5:10 6:4
Mean Age at Sampling (yrs ± SD) 61 ± 9.9 71.9 ± 4.3
Median disease duration (yrs ± SD) n/a 3.4 ± 1.57
Mean Aβ42 levels (pg/ml ± SD) 905.41 ± 237 695.6 ± 330.7
Mean h-tau levels (pg/ml ± SD) 136.58 ± 162 523 ± 432
Mean p-tau181 levels (pg/ml ± SD) 19.33 ± 11.11 52 ± 39
Validation cohort Control n = 15 LBD n = 17 PD n = 7 AD n = 16
Gender (M:F) 5:10 10:7 5:2 6:10
Mean Age at Sampling (yrs ± SD) 61 ± 9.9 72.1 ± 5.5 68.1 ± 3.4 78.1 ± 6.67
Median disease duration (yrs ± SD) 3.3 ± 1.9 4.1 ± 2.78
Mean Aβ42 levels (pg/ml ± SD) 905.41 ± 237 663.5 ± 268 886.4 ± 232 503.68 ± 165.88
Mean h-tau levels (pg/ml ± SD) 136.58 ± 162 679 ± 673 139 ± 93 733.77 ± 481.25
Mean p-tau levels (pg/ml ± SD) 19.33 ± 11.11 64.5 ± 48.8 26 ± 11 93.38 ± 31.55
Control, LBD, PD and 7 AD samples were received from centre 1 and 9 AD samples from centre 2. As the two centres share the same clinical workup for AD the
data in Table 2 has been combined
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PD was diagnosed according to current criteria [41].
Controls consisted of patients undergoing CSF analysis
for non-neurodegenerative conditions.
Ethics, consent and permissions: For centre 1 In-
formed consent to participate in this study was given by
all subjects or their caregivers. Centre 2: The study pro-
cedure has been approved by the ethical committees in
Gothenburg. All participants gave informed consent to
participate in research.
Clinical CSF was sampled according to a standard
protocol at both centres [42]. CSF samples were ob-
tained in polypropylene tubes by LP at the L4/L5 or L3/
L4 interspace, centrifuged at 4 °C and stored at ≤ −30 °C
until analysis. CSF cell counts, glucose and proteins were
determined. Routine analysis to exclude damage of the
Blood Brain Barrier (BBB) included measurement of
albumin by rate nephelometryand the intrathecal IgG
production. The albumin quotient (CSF albumin/serum
albumin) X 103 and the IgG index (CSF albumin/serum
albumin)/(CSF IgG/serum IgG) were calculated and
samples without BBB damage were used in the study
which confirm that the proteins measured in this study
are produced intrathecally and not leaking from the
periphery [43].
Aβ42, h-tau, p-tau 181 measurement
CSF total tau (h-tau) concentration was determined
using a sandwich enzyme-linked immunosorbent assay
(ELISA) (INNOTEST hTAU-Ag, Fujirebio, Ghent,
Belgium) specifically constructed to measure all tau iso-
forms irrespectively of phosphorylation status, as previ-
ously described [44]. CSF p-tau181 was measured using
a sandwich ELISA specifically detecting tau phosphory-
lated at amino acid 181 (INNOTEST PHOSPHO-TAU
(181P), Fujirebio, Ghent, Belgium). Aβ42 levels were
determined using a sandwich ELISA (INNOTEST ß-
AMYLOID [1–42], Fujirebio, Ghent, Belgium) [45].
Optimal cutoffs for identifying AD were as follows:
Aβ42 < 550 pg/mL; h-tau > 400 pg/mL and p-tau >
80 pg/mL [46].
Biomarker discovery: label-free proteomic analyses
(2D-LC-MSe)
Four hundred microliters of CSF was enriched for low
abundant proteins using a ‘Top20’ serum protein deple-
tion column as shown in Fig. 1 (Sigma, UK). Depleted
CSF was precipitated with 3 volumes of ice cold acetone
and double digested with Lys C and trypsin proteases
(Sigma, UK) as described previously [34]. Peptides were
offline fractionated using the high pH fractionation tech-
nique [47]. Yeast enolase peptide standard was added
and fractions analysed using label free quantitation on a
Waters QToF Premier mass spectrometer coupled to a
NanoAquity liquid chromatography system (Waters,
Manchester). Ten fractions were analysed using a 1.5 h
LC-MSe analyses as described previously in our labora-
tory [48]. Proteins were identified using Waters Protein-
Lynx Global server v 2.5 and a UniProt human reference
proteome database to which the sequence of P00924
yeast enolase and P00761 porcine trypsin were added
manually. Fixed modifications of carbamidomethylation
of cysteines, dynamic modifications of deamidation of
asparagine/glutamine and oxidation of methionine, up to
3 missed cleavage sites and maximum protein mass
800 kDa. False discovery rate was set at 4 %, mass toler-
ance for ion and fragments were set to auto. Only pro-
teins with >95 % confidence were exported for
differential expression analysis using Progenesis LC-MS
(non-linear dynamics) software.
Targeted proteomics: MRM-based triple quadrupole mass
spectral assay
Candidate markers were selected based on significance,
fold change and quality of the label free proteomics ana-
lysis data. Additional and potential neurodegenerative
biomarkers determined from the literature were also
included in the final multiplexed assay (see Table S2).
Representative quantotypic peptides for each protein
were determined from the label free proteomics data
(top 3 most abundant, optimum daughter spectra for
quantitation). Other peptides were selected using the
open source online global proteome machine MRM
database at www.thegpm.org [49]. Bioactive peptides
were designed by using either the N or C-terminus part
of the peptide to specify the native peptide from precur-
sor molecules. Custom synthesised peptides (Genscript,
USA) were used to optimise the peptide detection and
determine the retention time and identify unequivocally
the correct peak/s in CSF (individual chromatograms
provided in Additional file 2: Figure S1). Two transitions
were selected for each peptide. Clean transitions without
interfering peaks were used. Twenty nanograms of yeast
enolase protein standard (Sigma, UK) and 10–50 pmols
heavy labelled peptide standards (Thermo Scientific,
UK) were added to 100 μl of CSF. CSF was freeze dried
and trypsin digested as described previously [50]. A sin-
gle 35 μl injection of each CSF digest was injected onto
a Waters CORTECS UPLC C18 + Column, 90 Å,
1.6 μm, 3 mm × 100 mm column attached to a C18+
VanGuard pre-column. UPLC and MS tune conditions
were performed as described previously [34]. Dynamic
Multiple Reaction Monitoring was performed over a
10 min gradient with a minimum of 0.01 s dwell time
for quantitative transitions and minimum 12 data points
per peak on Waters Xevo TQ-S MS. QC runs of pooled
CSF digests were run in triplicate at the start of the run
and then every 10 injections. A CV within + /- 10 % for
each QC was considered acceptable. CSF was spiked
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with peptides to create standards with average concen-
trations of biomarker levels and analysed for intra- and
inter-batch variation. Chromatograms were analysed
using Waters Targetlynx software. Peptides were stan-
dardised by either using a spiked heavy labelled peptide
or to a yeast enolase peptide. Absolute levels were
obtained from standard curves. Standard curve linear-
ity of r2 > 0.9 was achieved for all calibration curves
(see Additional file 8: Figure S2). Data was exported
to excel and GraphPad Prism for statistical analysis.
Intra-batch variation was determined as being be-
tween 3.0 and 5.1 % and inter-batch variation being
7.6–8.5 % (n = 10, 3 consecutive days). A standard
curve 0–40 pmols / 100 μl CSF of each peptide was
analysed at the start and the end of the run for quan-
titation and performance standardisation (cv <10 %
was considered acceptable).
Statistical analysis
Analyses included data QC for peptide performance
(coefficient of variance), QC of sample preparation and
LC-MS/MS performance (yeast enolase), group compari-
sons (linear regression, non-parametric Mann Witney
test). Pearson correlation analysis was used only when
the data met parametric assumptions. In all other in-
stances non-parametric version, Spearman correlation,
was used and significant linearity determined by the F-
test. Group age ranges were checked for significant dif-
ference using a Kruskal-Wallis with Dunns post-test of
which no significant difference was confirmed.
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Additional file 2: Figure S1. Gene ontology analysis of CSF from
patients using the web-based Gene Set Analysis Toolkit (WebGestaldt).
(PPTX 364 kb)
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